Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study

作者：Kumar K V S Hari^*; Shaikh Altamash; Prusty Pitambar

来源：Diabetes Research and Clinical Practice, 2013, 100(2): E55-E58.

DOI：10.1016/j.diabres.2013.01.020

• Type 1 diabetes
• GLP-1
• Incretin modulators
• Exenatide
• Sitagliptin

Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.

• 出版日期2013-5